Cefepime tissue penetration in experimental acute pancreatitis

Pancreas

Volumn 26, Issue 2, 2003, Pages 117-121

  Gloor, Beat ^a   Worni, Mathias ^a   Strobel, Oliver ^b   Uhl, Waldemar ^b   Tcholakov, Oleg ^c   Müller, Christophe A ^b   Stahel, Philip F ^d   Droz, Sara ^a   Büchler, Markus W ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute pancreatitis; Antibiotic prophylaxis; Fourth generation cephalosporin; Microbiology; Tissue penetration

Indexed keywords

CEFEPIME; CERULETIDE; CILASTATIN PLUS IMIPENEM;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CITROBACTER FREUNDII; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; INFECTION RATE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PANCREAS NECROSIS; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; RAT; SERRATIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; BACTERIA; CAERULEIN; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LUNG; PANCREAS; PANCREATITIS, ACUTE NECROTIZING; RATS; RATS, WISTAR; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0037373695     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200303000-00005     Document Type: Article

References (41)

1. British Society of Gastroenterology. United Kingdom guidelines for the management of acute pancreatitis. Gut 1998;42:S1-13.
2. Uhl W, Buchler MW, Malfertheiner P. et al. A randomized, double-blind, multicenter trial of Octreotide in moderate to severe acute pancreatitis. Gut 1999;45:97-104.
3. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998;175:76-83.
4. Osman MO, Jensen SL. Acute pancreatitis: the pathophysiological role of cytokines and integrins. Dig Surg 1999;16:347-62.
5. Gloor B, Reber HA. Effects of cytokines and other inflammatory mediators on human acute pancreatitis. J Intensive Care Med 1998;13:305-12.
6. Gloor B, Müller AC, Worni M, et al. Late mortality in patients with severe acute pancreatitis. Br J Surg 2001;88:975-9.
7. Mutinga M, Rosenbluth A, Tenner SM, et al. Does mortality occur early or late in acute pancreatitis? Int J Pancreatol 2000;28:91-5.
8. Büchler MW, Gloor B, Müller CA, et al. Acute necrotizing pancreatitis: treatment strategy according to the status of infection. Ann Surg 2000;232:619-26.
9. Grewe M, Tsiotos GG, Luque de-Leon E, Sarr MG. Fungal infection in acute necrotizing pancreatitis. J Am Coll Surg 1999;188:408-14.
10. Gloor B, Muller CA, Womi M, et al. Pancreatic infection in severe pancreatitis: the role of fungus and multiresistant organisms. Arch Surg 2001;136:592-6.
11. Isenmann R, Beger HG. Natural history of acute pancreatitis and the role of infection. Baillieres Best Pract Res Clin Gastroenterol 1999:13:291-301.
12. Pederzoli P, Bassi C. Vesentini S, et al. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993;176:480-3.
13. Bassi C, Falconi M, Talamini G, et al. Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. Gastroenterology 1998;115:1513-7.
14. Sainio V, Kemppainen E, Puolakkainen P, et al. Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995;346:663-7.
15. Foitzik T, Hotz HG, Kinzig M, et al. Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis. Gut 1997;40:526-30.
16. Bassi C, Pederzoli P, Vesentini S, et al. Behavior of antibiotics during human necrotizing pancreatitis. Antimicrob Agents Chemother 1994;38:830-6.
17. Vouillamoz J, Entenza JM, Feger C, et al. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 2000;44:1789-95.
18. Mimoz O, Leotard S, Jacolot A, et al. Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. Antimicrob Agents Chemother 2000;44:885-90.
19. Lin JC. Yeh KM, Peng MY, et al. Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia. J Microbiol Immunol Inject 2001;34:131-7.
20. Breilh D, Saux MC, Delaisement C. et al. Pharmacokinetic population study to describe cefepime lung concentrations. Pulm Pharmacol Ther 2001;14:69-74.
21. Gloor B, Blinman TA, Rigberg DA, et al. Kupffer cell blockade reduces hepatic and systemic cytokine levels and lung injury in hemorrhagic pancreatitis in rats. Pancreas 2000;21:414-20.
22. Beger HG, Bittner R, Block S, et al. Bacterial contamination of pancreatic necrosis: A prospective clinical study. Gastroenterology 1986;91:433-8.
23. Bassi C. Falconi M, Girelli F, et al. Microbiological findings in severe pancreatitis. Surg Res Comm 1989;5:1-4.
24. Paye F, Rotman N, Radier C, Nouira R, Fagniez PL. Percutaneous aspiration for bacteriological studies in patients with necrotizing pancreatitis. Br J Surg 1998;85:755-9.
25. Luiten EJ, Hop WC, Lange JF, Bruining HA. Differential prognosis of gram-negative versus gram-positive infected and sterile pancreatic necrosis: results of a randomized trial in patients with severe acute pancreatitis treated with adjuvant selective decontamination. Clin Infect Dis 1997;25:811-6.
26. Wüst J, Frei R, the Swiss Cefepime Study Group. Multicenter study of the in vitro activity of cefepime in comparison with five other broad-spectrum antibiotics against clinical isolates of Gram-positive and Gram-negative bacteria from hospitalized patients in Switzerland. Clin Microbiol Infect 1999;5:262-9.
27. Gumaste VV. Prophylactic antibiotic therapy in the management of acute pancreatitis. J Clin Gastroenterol 2000;31:6-10.
28. Kramer KM, Levy H. Prophylactic antibiotics for severe acute pancreatitis: the beginning of an era. Pharmacotherapy 1999;19:592-602.
29. Powell JJ, Miles R, Siriwardena AK. Antibiotic prophylaxis in the initial management of severe acute pancreatitis. Br J Surg 1998;85:582-7.
30. Ratschko M, Fenner T, Lankisch PG. The role of antibiotic prophylaxis in the treatment of acute pancreatitis. Gastroenterot Clin North Am 1999;28:641-59.
31. Schmid SW, Uhl W, Friess H, Malfertheiner P, Büchler MW. The role of infection in acute pancreatitis. Gut 1999;45:311-6.
32. Golub R, Siddiqi F, Pohl D. Role of antibiotics in acute pancreatitis: a meta-analysis. J Gastrointest Surg 1998;2:496-503.
33. Burns GP, Stein TA, Kabnick LS. Blood-pancreatic juice barrier to antibiotic excretion. Am J Surg 1986;151:205-8.
34. Büchler MW, Malfertheiner P, Friess H, Beger HG. The penetration of antibiotics into human pancreas. Infection 1989;17:20-5.
35. Büchler M, Malfertheiner P, Friess H, et al. Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology 1992;103:1902-8.
36. Saglamkaya UMM, Yasar M, Simsek I, Mas NN, Kocabalkan F. Penetration of meropenem and cefepime into pancreatic tissue during the course of experimental acute pancreatitis. Pancreas 2002;24:264-8.
37. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10; quiz 11-2.
38. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
39. Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 2000;22:66-75.
40. Forgue ST, Shyu WC, Gleason CR, Pitman KA, Barbhaiya RH. Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys. Antimicrob Agents Chemother 1987;31:799-804.
41. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg 1997;132:1294-302.